Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients

Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non-diabetic HF outpatients is unknown. Methods: Adult non-diabetic HF patients with a left ventricular ejection fraction (LVEF)

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2022-05, Vol.11 (10), p.2935
Main Authors: Reis, João, Teixeira, Ana Rita, Gonçalves, António Valentim, Moreira, Rita Ilhão, Silva, Tiago Pereira, Timóteo, Ana Teresa, Ferreira, Rui Cruz
Format: Article
Language:English
Subjects:
Anaerobic threshold
Antidiabetics
Blood pressure
Cardiovascular disease
Clinical medicine
Diabetes
Ejection fraction
Fitness equipment
Heart failure
Heart rate
Hemoglobin
Hospitalization
Mortality
Patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non-diabetic HF outpatients is unknown. Methods: Adult non-diabetic HF patients with a left ventricular ejection fraction (LVEF)
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11102935